Wailoo A, Bansback N, Chilcott J
Rheumatology (Oxford). 2008 Feb;47(2):119-20
A collection of work and information about decision making in health
Display multiple categories by selecting below
-
Most important contributions
- Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis
- Impact of the recall period on measuring health utilities for acute events
- Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis
- Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK
- Using a discrete choice experiment to estimate societal health state utility values
Translator
Get smart with the Thesis WordPress Theme from DIYthemes.